Changes in US stocks | The acquisition of AtaiBeckley Inc. (ATAI.US) with a whopping $3.8 billion takeover of ATAIBeckley Inc. (ATAI.US), which opened and soared more than 30%

The Zhitong Finance App learned that on Thursday, the opening of ATAIBeckley Inc. (ATAI.US) soared by more than 30% to a new high during the year, and now reports $7.05. According to the news, LLY.US (LLY.US) has agreed to acquire AtaiBeckley Inc., for up to $3.8 billion, which highlights the growing interest of large pharmaceutical companies in hallucinogenic drugs (psychedelic medicine), which was once a marginal field. According to a statement on Thursday, Eli Lilly will pay $6.75 per share in cash and up to $2.50 per share if drug development milestones are reached. The underlying price was 26% higher than ATaiBeckley's close on Wednesday.

AtaiBeckley is exploring options to sell or collaborate on its flagship drug called BPL-003. The deal deepens Eli Lilly's long-term presence in the field of neuroscience medicine. This is a critical moment in the development of hallucinogenic drugs. After years on the edge of drug development, the field was fueled by the success of Johnson & Johnson Spravato, promising clinical trial results, and recent support from the Trump administration. Analysts say the hallucinogen treatment market could reach $7 billion in sales by 2032.